Abstract:Activation of the p53 tumor suppressor can lead to cell cycle arrest. The key mechanism of p53-mediated arrest is transcriptional downregulation of many cell cycle genes. In recent years it has become evident that p53-dependent repression is controlled by the p53–p21–DREAM–E2F/CHR pathway (p53–DREAM pathway). DREAM is a transcriptional repressor that binds to E2F or CHR promoter sites. Gene regulation and deregulation by DREAM shares many mechanistic characteristics with the retinoblastoma pRB tumor suppressor that acts through E2F elements. However, because of its binding to E2F and CHR elements, DREAM regulates a larger set of target genes leading to regulatory functions distinct from pRB/E2F. The p53–DREAM pathway controls more than 250 mostly cell cycle-associated genes. The functional spectrum of these pathway targets spans from the G1 phase to the end of mitosis. Consequently, through downregulating the expression of gene products which are essential for progression through the cell cycle, the p53–DREAM pathway participates in the control of all checkpoints from DNA synthesis to cytokinesis including G1/S, G2/M and spindle assembly checkpoints. Therefore, defects in the p53–DREAM pathway contribute to a general loss of checkpoint control. Furthermore, deregulation of DREAM target genes promotes chromosomal instability and aneuploidy of cancer cells. Also, DREAM regulation is abrogated by the human papilloma virus HPV E7 protein linking the p53–DREAM pathway to carcinogenesis by HPV. Another feature of the pathway is that it downregulates many genes involved in DNA repair and telomere maintenance as well as Fanconi anemia. Importantly, when DREAM function is lost, CDK inhibitor drugs employed in cancer treatment such as Palbociclib, Abemaciclib and Ribociclib can compensate for defects in early steps in the pathway upstream from cyclin/CDK complexes. In summary, the p53–p21–DREAM–E2F/CHR pathway controls a plethora of cell cycle genes, can contribute to cell cycle arrest and is a target for cancer therapy.

Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM

Cell cycle regulation: p53-p21-RB signaling

Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex

RB, p130 and p107 differentially repress G1/S and G2/M genes after p53 activation

The p21CIP1-CDK4-DREAM axis is a master regulator of genotoxic stress-induced cellular senescence

Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks

p53-dependent gene repression through p21 is mediated by recruitment of E2F4 repression complexes

P130/p107/p105rb-Dependent Transcriptional Repression During DNA-damage-induced Cell-Cycle Exit at G2

The Establishment of a Hyperactive Structure Allows the Tumour Suppressor Protein p53 to Function through P-TEFb during Limited CDK9 Kinase Inhibition

Awakening guardian angels: drugging the p53 pathway

Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination.

The Phosphatase Mkp1 Is A Transcriptional Target Of P53 Involved In Cell Cycle Regulation

HDAC activity is dispensable for repression of cell-cycle genes by DREAM and E2F:RB complexes

p53 and E2f: partners in life and death

CDK8 Is a Stimulus-Specific Positive Coregulator of p53 Target Genes

Evolutionarily Conserved Multisubunit RBL2/p130 and E2F4 Protein Complex Represses Human Cell Cycle-Dependent Genes in Quiescence.

Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl

Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis

B-MYB is required for recovery from the DNA damage-induced G2 checkpoint in p53 mutant cells

P21 Disrupts the Interaction Between Cdk2 and the E2F-p130 Complex.

Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F